

Skin Cancer Hub Information to support prevention and early diagnosis



Malignant melanoma: incidence, mortality and survival rates in the East of England Strategic Health Authority and England

May 2012

This factsheet presents data for ICD-10 C43 "Malignant melanoma of skin". The latest available incidence, mortality and survival data have been used.

Incidence rates

The 3-year average age-standardised incidence rate of malignant melanoma in the East of England Strategic Health Authority (SHA) for males and females followed the same trend as the rate for England: an increase in incidence over the previous 20 years. From 1985–87 to 2001-03 generally the incidence for males and females in East of England SHA was higher than for England. In 2007–09 the age-standardised incidence rate of malignant melanoma for males was 17.6 (East of England SHA) and 15.8 (England) per 100,000 population and the rate for females was 17.0 (East of England SHA) and 16.3 (England) per 100,000 population. From 1985–97 to 1995–97, the age-standardised incidence rate was lower for males than for females.




Figure 1: Malignant melanoma – 3-year average age-standardised incidence rates for males, 1985–2009

Source: UK Cancer Intelligence Service (UKCIS)








Figure 2: Malignant melanoma – 3-year average age-standardised incidence rates for females, 1985–2009

Source: UK Cancer Intelligence Service (UKCIS)

Mortality rates

The 3-year average age-standardised mortality rate from malignant melanoma in the East of England SHA for males and females followed a similar trend as the rate for England over the last 20 years: for males the rate increased and for females it stayed constant despite some fluctuations in the SHA rates. In 2008–10 the 3-year average age-standardised mortality rate from malignant melanoma for males was 3.4 (East of England SHA) and 3.2 (England) per 100,000 population and for females the rate was 2.2 (East of England SHA) and 2.1 (England) per 100,000 population. From 1997–99, the 3-year average age-standardised mortality rate stan females.




Figure 3: Malignant melanoma – 3-year average age-standardised mortality rates for males, 1985–2010

Source: UK Cancer Intelligence Service (UKCIS)





Figure 4: Malignant melanoma – 3-year average age-standardised mortality rates for females, 1985-2010

Source: UK Cancer Intelligence Service (UKCIS)

Survival rates

Five-year relative survival rates from malignant melanoma showed little difference between the East of England SHA and England for both males and females diagnosed in 2003-05; the survival rate for males was 82.7% in the East of England SHA and 83.0% in England, while for females the rates were 90.9% in the East of England SHA and 91.6% in England. Comparing survival for people diagnosed in 1985–87 and 2003–05, relative survival increased by 18.2% for males and by 6.6% for females in the East of England SHA.



England

East of England

Figure 5: Malignant melanoma – 5-year relative survival rates for males diagnosed in 1985–2005,

Source: UK Cancer Intelligence Service (UKCIS)




Figure 6: Malignant melanoma – 5-year relative survival rates for females diagnosed in 1985–2005, 3-year average

Source: UK Cancer Intelligence Service (UKCIS)

Further information

Contact details:

South West Public Health Observatory Grosvenor House 149 Whiteladies Road Clifton, Bristol BS8 2RA

© South West Public Health Observatory 2012

T:	0117 970 6474
F:	0117 970 6481
E:	info@swpho.nhs.uk

About the South West Public Health Observatory

The South West Public Observatory (SWPHO) is part of a network of 12 public health observatories working across the five nations of England, Scotland, Wales, Northern Ireland and the Republic of Ireland. The nine Public Health Observatories in England work together through a single work programme which contains both national and local elements. We produce information, data and intelligence on people's health and health care for practitioners, policy makers and the wider community. Our expertise lies in turning information and data into meaningful health intelligence to support decision makers.

On behalf of the Department of Health, the SWPHO works in partnership with the NHS, local authorities, researchers, national agencies as well as agencies in the South West.

The SWPHO incorporates the National Drug Treatment Monitoring System South West (NDTMS–SW), and in April 2005 merged with the South West Cancer Intelligence Service (SWCIS).

For more information about the SWPHO and its partner organisations, please visit www.swpho.nhs.uk